A 2024 Nature Communications study (Wang et al., including NIH scientist Nora Volkow) analyzed real-world records from 83,825 patients and found semaglutide associated with a 50 to 56% lower rate of alcohol use disorder incidence and recurrence compared with other anti-obesity medications
Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, and Gribble FM
Glycaemic efficacy Compared with placebo, reductions in HbA 1c levels ranged between 17.71 mmol/mol (1.62%) with tirzepatide 5 mg and 22.35 mmol/mol (2.06%) with tirzepatide 15 mg (Fig
In parallel, other researchers are exploring alternative models of use, such as starting with GLP-1 drugs for a short period to achieve initial weight loss, then switching to lifestyle programs, meal replacements or older medications for maintenance rather than keeping patients on GLP-1 drugs for the rest of their lives
On BPC-157, eight members of the committee voted yes, six voted no, and one abstained
NPS Pharmaceuticals [online], (2012)
